Pembrolizumab (monotherapy)
Treatment for Uterine Cancer
Typical Dosage: 200mg IV every 3 weeks or 400mg IV every 6 weeks
Effectiveness
60%
Safety Score
40%
Clinical Trials
36
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
200mg IV every 3 weeks or 400mg IV every 6 weeks
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$10,000
Side Effect Mgmt:$5,000
Total Annual:$165,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$104,000/QALY
QALYs Gained
1.14
Outcome-Based Costs
Cost per Responder
$412,500
Cost per Remission
$1,650,000
Comparison vs Chemotherapy (Doxorubicin or Paclitaxel)
Cost Difference
+$65,000/year
More expensive
QALY Difference
+1.14 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab (monotherapy) Outcomes
for Uterine Cancer
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+40%
Remission Rate
+10%
Common Side Effects
Fatigue
+40%
Musculoskeletal pain
+25%
Diarrhea
+25%
Rash
+20%
Immune-related adverse events (colitis, hepatitis, pneumonitis, endocrinopathies)
+15%
Sources:
Active Clinical Trials
8 active trials recruiting for Pembrolizumab (monotherapy) in Uterine Cancer
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619RECRUITINGPHASE1, PHASE2
160 participants
INTERVENTIONAL
Los Angeles, United States +44 more
Started: Jan 20, 2026
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430RECRUITINGPHASE1, PHASE2
365 participants
INTERVENTIONAL
Los Angeles, United States +12 more
Started: Mar 23, 2023
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692ACTIVE NOT RECRUITINGPHASE1, PHASE2
160 participants
INTERVENTIONAL
San Diego, United States +24 more
Started: Aug 27, 2021
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168RECRUITINGPHASE1
200 participants
INTERVENTIONAL
San Diego, United States +8 more
Started: Nov 7, 2025
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981RECRUITINGPHASE1
130 participants
INTERVENTIONAL
Detroit, United States +10 more
Started: Apr 3, 2023
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
NCT07749586RECRUITINGPHASE1, PHASE2
499 participants
INTERVENTIONAL
New York, United States +3 more
Started: Jul 29, 2026
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762RECRUITINGPHASE1
714 participants
INTERVENTIONAL
Birmingham, United States +61 more
Started: Oct 25, 2022
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
NCT06502743RECRUITINGPHASE2
92 participants
INTERVENTIONAL
Kyeonggi-do, South Korea +5 more
Started: Sep 12, 2024
Completed Clinical Trials
4 completed trials for Pembrolizumab (monotherapy) in Uterine Cancer
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
NCT06894771COMPLETEDPHASE1
5 participants
INTERVENTIONAL
Hackensack, United States +6 more
Started: Apr 23, 2025
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
NCT02635672COMPLETEDPHASE1
110 participants
INTERVENTIONAL
Springdale, United States +15 more
Started: Feb 10, 2016
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
NCT03674567COMPLETEDPHASE1, PHASE2
323 participants
INTERVENTIONAL
Gilbert, United States +34 more
Started: Sep 25, 2018
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
NCT03849469COMPLETEDPHASE1
78 participants
INTERVENTIONAL
Encinitas, United States +27 more
Started: May 29, 2019
Showing 20 of 43 total trials